OmicsEdge Forms Strategic Partnership with Almaden Genomics

OmicsEdge has launched an industry leading drug discovery service that leverages Almaden’s g.nome™ platform to streamline the iteration process. The service makes it easy for labs to conduct a quick analysis of a patient or trial participant’s medical condition and genomics, gaining valuable insight in genomic criteria and how it affects elevated risk. The service can be used to significantly accelerate the drug discovery process and eliminate trial-and-error with abilities such as identifying causal variants that make ideal drug targets.

“Most clinical trials do not take genomics into account as a confounding factor, even though they play a major role in both results and analysis,” said David Gascoigne, CEO of Almaden Genomics. “Together with OmicsEdge, our technology allows those conducting or pursuing clinical trials to incorporate genomics into the selection of targets for discovery.”

OmicsEdge is a science-first bioinformatics company, and is the only one utilizing ancestry-informed Polygenic Risk Scores based on over 83 million genetic variants and benchmarking. Its team of software engineers, data scientists, MDs and geneticists leads the industry in polygenic risk scoring, imputation, and ancestry determination. OmicsEdge partners with clients on bioinformatic projects including GWAS analysis, RNA-Seq, and spatial genomics with use cases in supporting pharmaceutical and biotechnology companies during drug discovery, diagnostic development, and post-market surveillance work.

“Our team has decades of experience in helping organizations with their genomics and bioinformatics projects, from development and execution to publication,” said Puya Yazdi, M.D., Chief Science Officer and Chief Medical Officer of OmicsEdge. “Almaden’s g.nome platform is an invaluable tool in our work that accelerates development of state-of-the-art pipelines, enabling us to iterate quickly and efficiently, freeing our team to focus on answering important biological questions.”

Launched in 2022, g.nome revolutionizes bioinformatic pipeline building with an advanced visual drag-and-drop workflow builder and curated library of tools to condense what previously has taken months to mere hours. Most pharma and research institutes still perform the laborious work of building pipelines with solutions being hand-coded by a limited number of highly skilled bioinformaticians. The g.nome platform, which integrates with Jupyter Notebook, eliminates the need for coding in most applications and allows the broader research team to actively participate in the pipeline iteration and executing processes.

Visit AITechPark for cutting-edge Tech Trends around AI, ML, Cybersecurity, along with AITech News, and timely updates from industry professionals!

Related posts

Genomic Vision: 2021 Annual Results

Business Wire

Fore Genomics is using DNAnexus platform for its FORESITE 360 test

Business Wire

GeneASIC Technologies to Exhibit New Genome Data Analysis System

PR Newswire